** Shares of gene therapy maker bluebird bio rise as much as 2.3% to 49 cents premarket; last up 1%
** Co says it will cut approximately 25% of its workforce as part of its restructuring to optimize cash flow break-even in H2 2025
** Restructuring also to reduce operating cash expenses by 20% - co
** BLUE says it will incur aggregate charged worth $3.7 mln as a result of restructuring, to be paid out through fiscal year ending Dec. 31
** As of June 30, 2024, co had 375 full-time employees
** As of last close, stock down 64.6% YTD
(Reporting by Kashish Tandon in Bengaluru)
((Kashish.tandon@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.